Interferon conjugates

Details Interferon conjugates Interferon conjugates

2007-04-10

2007-04-10

Russel, Jeffrey Edwin (Department: 1654)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C530S351000, C530S409000

Reexamination Certificate

active

10377892

ABSTRACT:
Physiologically active PEG-IFNα conjugate having a formula as follows:

REFERENCES:
patent: 4609546 (1986-09-01), Hiratani
patent: 4681848 (1987-07-01), Tsukamoto et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4911888 (1990-03-01), Fikentscher et al.
patent: 4935465 (1990-06-01), Garman
patent: 5122614 (1992-06-01), Zalipsky
patent: 5145773 (1992-09-01), Albino et al.
patent: 5281698 (1994-01-01), Nitecki
patent: 5359030 (1994-10-01), Ekwuribe et al.
patent: 5382567 (1995-01-01), Karasiewicz et al.
patent: 5438040 (1995-08-01), Ekwuribe
patent: 5595732 (1997-01-01), Hakini et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5762923 (1998-06-01), Gross et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 6113906 (2000-09-01), Greenwald et al.
patent: 2004/0185489 (2004-09-01), Certa et al.
patent: 0 400 472 (1990-12-01), None
patent: 510 356 (1992-10-01), None
patent: 0 576 192 (1993-12-01), None
patent: 0 103 898 (1994-03-01), None
patent: 0 593 868 (1994-04-01), None
patent: 0 736 303 (1996-10-01), None
patent: WO 84/04745 (1984-12-01), None
patent: WO 87/00056 (1987-01-01), None
patent: WO 92/21691 (1992-12-01), None
patent: WO 95/11924 (1995-05-01), None
patent: WO 95/13090 (1995-05-01), None
patent: WO 95/21629 (1995-08-01), None
patent: WO 96/11953 (1996-04-01), None
patent: WO 96/21469 (1996-07-01), None
patent: WO 97/18832 (1997-05-01), None
Morpurgo, et al., “Covalent Modification of Mushroom Tyrosinase with Different Amphiphic Polymers for Pharmaceutical and Biocatalysis Applications”,Applied Biochemistry and Biotechnology, (1996), 56(1): 59-72.
C.S. Monfardini, et al., A Branched Monomethoxypoly(ethylene glycol) for protein modification,Bioconjugate Chem. (1995) 6:62-69.
S. Pestka, The Human Interferons-From Protein Purification and Sequence to Cloning and Expression in Bacteria: Before, Between, and Beyond.Arch. Biochem. Biophys. (1983) 221(1): 1-37.
S. Pestka, “The Purification and Manufacture of Human Interferons”Sci. Am.(1983) 249(2):36-43.
S. Rubenstein, et al., “Convenient Assay for Interferons,”J. Virol. (1981) 37:755-758.
Y. Inada, et al., “Polyethylene Glycol(PEG)-Protein Conjugates: Application to Biomedical and Biotechnological Processes, J. Bioact. and Compatible Polymers,”J. Bioact. and Compatible Polymers,(1990) 5:343-364.
C. Delgado, et al., “The Uses and Properties of PEG-Linked Proteins,”Critical Reviews in Therapeutic Drug Carrier Sysytems,(1992) 9(3,4):249-304.
N.V. Katre, et al., “The Conjugation of Proteins with PEG and Other Polymers; Altering Properties to Enhance Their Therapeutic Potential,”Advance Drug Delivery Reviews,(1993) 10:91-114.
N.V. Katre, et al,. “Chemical Modifications of Interleukin-2 by Polyethyleneglycol Increases Its Potency in the Murine Meth A Sarcoma Model,”Proc. Natl. Acad. Sci. USA,(1987) 84:1487-1491.
R.Satake-Ishikawa, et al., “Chemical Modification of Recombinant Human Granulocyte Colony Stimulating Factor by Polyethyleneglycol Increases Its Biological Activity In Vivo,”Cell Structure and Function,(1992) 17:157-160.
Y. Tsutsumi, et al., “Chemical Modification of Natural Tumor Necrosis Factor-α With Polyethylene Glycol Increases Its Potency, ,”JpnJ. Cancer Res.,(1994) 85:9-12.
H. Inoue, et al., “A Highly Enhanced Thrombopoietic Activity By Polyethylene Glycol-Modified Recombinant IL-6, J. Lab. Clin. Med.,”J. Lab. Clin. Med.,(1994) 124:529-536.
S.M. Chamow, et al., “Modification of CD4 Immunoadhesion with Monomethoxypoly (Ethylene Glycol) Aldehyde Via Reductive Alkylation,”Bioconj. Chem..,(1994) 5:133-140.
E.C. Borden, et al., Comparative Antiproliferative Activity In Vitro of Natural Interferons α and β for Diploid and Transformed Human Cells,Can. Res.(1982) 42: 4948-4953.
Yoshinaga, et al.,J. Bioact. Compatible Polym. (1987) 4:17-24.
Yoshinaga, et al.,J. Bioact. Compatible Polym. (1987) 2:49-56.
Matsushima, A., et al.,Chem Letter Pages(1980) pp. 773-776.
Yamasaki, et al.,Agric Biol. Chem. (1990) 54:2635-2640.
Yamasaki, et al.,Agric Biol. Chem. (1988) 52:2125-2127.
Truitt, et al., “Pharmacodynamic and Preliminary Pharmacokinetic Evaluation of Pegylated Derivatives of Interferon-Alpha 2A,”Proc. Annu. Meet AM Assoc. Canc. Res., (1994) vol. 35, A2370.
Palleroni, et al., “The in Vivo Fate of PEG-Interferon Alpaha 2a (ro 25-3036) in Tumor Bearing Mice (Meeting Abstract),”Proc. Annu. Meet AM Assoc Canc. Res. (1994) vol. 35, A1845.
Monkarsh, et al., Positional Isomers of Monopegylated Interferon α-2a: Isolation, Characterization, and Biological Activity,Analytical Biochemistry(1997), vol. 247, pp. 434-440.
Lam, et al., “Dose-Dependent Acute Clearance of Hepatitis C Genotype 1 Virus With Interferon Alpha,”Hepatology. (1997) 26(1):226-231.
Fung, et al., “Strategies For The Preparation and Characterization of Polyethylene Glycol (PEG) Conjugated Pharmaceutical Proteins,”Polym. Prep. (1997) 38: 565-566.

Affiliated with

Also associated with

Rating

Interferon conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Interferon conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon conjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3790235